ALPMY:OTC-Astellas Pharma Inc (USD)

COMMON STOCK | Drug Manufacturers-General | OTC

Last Closing Price

USD 16.68

Change

-0.01 (-0.06)%

Market Cap

USD 30.59B

Volume

0.18M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Astellas Pharma Inc (ALPMY) Stock Analysis:
Based on the Astellas Pharma Inc stock forecasts from 0 analysts, the average analyst target price for Astellas Pharma Inc is not available over the next 12 months. Astellas Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Astellas Pharma Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Astellas Pharma Inc’s stock price was USD 16.68. Astellas Pharma Inc’s stock price has changed by +0.18% over the past week, +0.66% over the past month and +2.52% over the last year.

No recent analyst target price found for Astellas Pharma Inc
No recent average analyst rating found for Astellas Pharma Inc

About

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid le ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RHHBF Roche Holding AG

N/A

USD347.70B 24.48 15.89
RHHBY Roche Holding AG

-0.01 (-0.02%)

USD347.70B 22.57 15.89
RHHVF Roche Holding AG

+3.23 (+0.82%)

USD345.90B 22.26 15.89
NVSEF Novartis AG

-0.12 (-0.14%)

USD200.93B 20.49 11.03
AZNCF AstraZeneca PLC

+0.67 (+0.56%)

USD182.98B 109.05 24.31
SNYNF Sanofi

N/A

USD131.71B 18.76 12.23
GLAXF GlaxoSmithKline plc

-0.81 (-3.47%)

USD115.23B 19.64 12.36
BAYRY Bayer Aktiengesellschaft

+0.13 (+0.88%)

USD59.19B 352.28 12.00
BAYZF Bayer Aktiengesellschaft

+0.44 (+0.75%)

USD59.19B 350.18 12.00
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD54.61B 24.37 0.14

ETFs Containing ALPMY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.52% 62% D- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.52% 62% D- 57% F
Trailing 12 Months  
Capital Gain 2.52% 59% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.52% 54% F 52% F
Trailing 5 Years  
Capital Gain 23.97% 52% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.97% 48% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain 7.29% 65% D 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.29% 54% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 14.30% 76% C 90% A-
Risk Adjusted Return 51.00% 59% F 74% C
Market Capitalization 30.59B 62% D- 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.33 32% F 24% F
Price/Book Ratio 2.30 54% F 41% F
Price / Cash Flow Ratio 0.10 89% B+ 48% F
EV/EBITDA 0.12 78% C+ 79% C+
Management Effectiveness  
Return on Equity 8.69% 38% F 59% F
Return on Invested Capital 8.29% 41% F 68% D+
Return on Assets 7.05% 46% F 87% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.66 32% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector